On Monday, Quince Therapeutics Inc (NASDAQ: QNCX) opened higher 2.83% from the last session, before settling in for the closing price of $1.06. Price fluctuations for QNCX have ranged from $0.51 to $2.45 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 40.08% at the time writing. With a float of $32.75 million, this company’s outstanding shares have now reached $44.00 million.
Let’s determine the extent of company efficiency that accounts for 36 employees. In terms of profitability, gross margin is 0.0%, operating margin of -31095.24%, and the pretax margin is -33774.4%.
Quince Therapeutics Inc (QNCX) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Quince Therapeutics Inc is 25.77%, while institutional ownership is 11.06%. The most recent insider transaction that took place on Aug 30 ’24, was worth 53,900. In this transaction CEO AND CHIEF MEDICAL OFFICER of this company bought 77,000 shares at a rate of $0.70, taking the stock ownership to the 843,941 shares. Before that another transaction happened on Aug 29 ’24, when Company’s CEO AND CHIEF MEDICAL OFFICER bought 77,500 for $0.69, making the entire transaction worth $53,475. This insider now owns 766,941 shares in total.
Quince Therapeutics Inc (QNCX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 40.08% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 33.51% during the next five years compared to 7.53% growth over the previous five years of trading.
Quince Therapeutics Inc (NASDAQ: QNCX) Trading Performance Indicators
Check out the current performance indicators for Quince Therapeutics Inc (QNCX). In the past quarter, the stock posted a quick ratio of 6.05.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.31, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -0.68 in one year’s time.
Technical Analysis of Quince Therapeutics Inc (QNCX)
Looking closely at Quince Therapeutics Inc (NASDAQ: QNCX), its last 5-days average volume was 1.21 million, which is a jump from its year-to-date volume of 0.19 million. As of the previous 9 days, the stock’s Stochastic %D was 39.51%. Additionally, its Average True Range was 0.10.
During the past 100 days, Quince Therapeutics Inc’s (QNCX) raw stochastic average was set at 10.41%, which indicates a significant decrease from 44.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.54% in the past 14 days, which was higher than the 61.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2636, while its 200-day Moving Average is $1.2561. However, in the short run, Quince Therapeutics Inc’s stock first resistance to watch stands at $1.1466. Second resistance stands at $1.2032. The third major resistance level sits at $1.2465. If the price goes on to break the first support level at $1.0467, it is likely to go to the next support level at $1.0034. Should the price break the second support level, the third support level stands at $0.9468.
Quince Therapeutics Inc (NASDAQ: QNCX) Key Stats
There are currently 44,123K shares outstanding in the company with a market cap of 48.09 million. Presently, the company’s annual sales total 0 K according to its annual income of -56,830 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -12,460 K.
